DE602004016127D1 - Antagonisten der opioidrezeptoren - Google Patents
Antagonisten der opioidrezeptorenInfo
- Publication number
- DE602004016127D1 DE602004016127D1 DE602004016127T DE602004016127T DE602004016127D1 DE 602004016127 D1 DE602004016127 D1 DE 602004016127D1 DE 602004016127 T DE602004016127 T DE 602004016127T DE 602004016127 T DE602004016127 T DE 602004016127T DE 602004016127 D1 DE602004016127 D1 DE 602004016127D1
- Authority
- DE
- Germany
- Prior art keywords
- antagonists
- opioid receptors
- racemate
- diastereomer
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45324303P | 2003-03-07 | 2003-03-07 | |
| PCT/US2004/003368 WO2004080996A1 (en) | 2003-03-07 | 2004-03-01 | Opioid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004016127D1 true DE602004016127D1 (de) | 2008-10-09 |
Family
ID=32990743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004016127T Expired - Lifetime DE602004016127D1 (de) | 2003-03-07 | 2004-03-01 | Antagonisten der opioidrezeptoren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7396943B2 (de) |
| EP (1) | EP1606275B1 (de) |
| JP (1) | JP2006519855A (de) |
| CN (1) | CN1753884A (de) |
| AT (1) | ATE406360T1 (de) |
| AU (1) | AU2004220113A1 (de) |
| BR (1) | BRPI0408108A (de) |
| CA (1) | CA2513791A1 (de) |
| DE (1) | DE602004016127D1 (de) |
| ES (1) | ES2312972T3 (de) |
| MX (1) | MXPA05009367A (de) |
| WO (1) | WO2004080996A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| UA80437C2 (en) * | 2002-09-19 | 2007-09-25 | Lilly Co Eli | Diaryl ethers as opioid receptor antagonist |
| DK2368553T3 (en) | 2003-04-08 | 2015-02-09 | Progenics Pharm Inc | Pharmaceutical preparation comprising methylnaltrexone |
| BRPI0409263A (pt) * | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
| WO2005061442A1 (en) | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
| AU2004312312A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Opioid receptor antagonists |
| GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| CA2558652A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2005090286A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| EP1751103B1 (de) | 2004-03-15 | 2009-01-14 | Eli Lilly And Company | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
| CA2557794A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| EP1856053A1 (de) | 2005-01-14 | 2007-11-21 | Millennium Pharmaceuticals, Inc. | Cinnamid- und hydrocinnamid-derivate mit raf-kinase hemmender aktivität |
| US9662390B2 (en) * | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| EP1943226A2 (de) | 2005-10-13 | 2008-07-16 | Smithkline Beecham Corporation | Phenolether als modulatoren der opioidrezeptoren |
| WO2008032156A1 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| CA2682129A1 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
| ES2493590T3 (es) | 2007-03-29 | 2014-09-12 | Wyeth Llc | Antagonistas de receptores opioides periféricos y usos de los mismos |
| WO2008121348A2 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| EP2152671A1 (de) | 2007-05-22 | 2010-02-17 | Prosidion Limited | Bicyclische aryl- und heteroarylverbindungen zur behandlung von stoffwechselerkrankungen |
| US8063247B2 (en) | 2007-09-07 | 2011-11-22 | Prosidion Limited | Bicyclic aryl and heteroaryl receptor modulators |
| AR070158A1 (es) * | 2008-01-22 | 2010-03-17 | Lilly Co Eli | Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa |
| CA2713568C (en) | 2008-02-06 | 2016-09-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| EP2278966B1 (de) | 2008-03-21 | 2019-10-09 | The University of Chicago | Behandlung mit opioid-antagonisten und mtor-inhibitoren |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| WO2010096790A1 (en) * | 2009-02-23 | 2010-08-26 | Mallinckrodt Inc. | (+)-morphinananium n-oxides and processes for their production |
| MX342548B (es) * | 2009-09-18 | 2016-10-04 | Merck Sharp & Dohme Corp * | Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. |
| WO2012051502A1 (en) * | 2010-10-14 | 2012-04-19 | University Of Utah Research Foundation | Methods and compositions related to neuroactive thiazoline compounds |
| CN106117195A (zh) * | 2016-06-09 | 2016-11-16 | 青岛辰达生物科技有限公司 | 一种用于治疗白血病的药物达沙替尼的合成方法 |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| CN112341404B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 噻唑类衍生物或盐、异构体、其制备方法及用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891379A (en) * | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
| AUPP796798A0 (en) * | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| DK1347971T3 (da) * | 2000-12-21 | 2006-05-15 | Bristol Myers Squibb Co | Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien |
| ATE372768T1 (de) | 2001-03-29 | 2007-09-15 | Lilly Co Eli | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste |
-
2004
- 2004-03-01 BR BRPI0408108-0A patent/BRPI0408108A/pt not_active Application Discontinuation
- 2004-03-01 US US10/544,286 patent/US7396943B2/en not_active Expired - Fee Related
- 2004-03-01 AT AT04716082T patent/ATE406360T1/de not_active IP Right Cessation
- 2004-03-01 MX MXPA05009367A patent/MXPA05009367A/es unknown
- 2004-03-01 EP EP04716082A patent/EP1606275B1/de not_active Expired - Lifetime
- 2004-03-01 AU AU2004220113A patent/AU2004220113A1/en not_active Abandoned
- 2004-03-01 CN CNA2004800050293A patent/CN1753884A/zh active Pending
- 2004-03-01 CA CA002513791A patent/CA2513791A1/en not_active Abandoned
- 2004-03-01 JP JP2006508678A patent/JP2006519855A/ja not_active Withdrawn
- 2004-03-01 DE DE602004016127T patent/DE602004016127D1/de not_active Expired - Lifetime
- 2004-03-01 ES ES04716082T patent/ES2312972T3/es not_active Expired - Lifetime
- 2004-03-01 WO PCT/US2004/003368 patent/WO2004080996A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006519855A (ja) | 2006-08-31 |
| US20060166987A1 (en) | 2006-07-27 |
| ATE406360T1 (de) | 2008-09-15 |
| WO2004080996A1 (en) | 2004-09-23 |
| ES2312972T3 (es) | 2009-03-01 |
| MXPA05009367A (es) | 2005-11-04 |
| EP1606275A1 (de) | 2005-12-21 |
| AU2004220113A1 (en) | 2004-09-23 |
| CN1753884A (zh) | 2006-03-29 |
| CA2513791A1 (en) | 2004-09-23 |
| BRPI0408108A (pt) | 2006-03-01 |
| US7396943B2 (en) | 2008-07-08 |
| EP1606275B1 (de) | 2008-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406360T1 (de) | Antagonisten der opioidrezeptoren | |
| ATE377589T1 (de) | 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten | |
| DE60302157D1 (de) | Opioidrezeptorantagonisten | |
| HRP20050253B1 (hr) | Diaril eteri kao opioid antagonisti opioidnih receptora | |
| CO5680444A2 (es) | Agonista a-2 no sedante 1-(2,3-dimetil-fenil)-etil-1,3-dihidro-imidazol-2-tiona | |
| TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
| ATE545413T1 (de) | Antagonisten des opioidrezeptors | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| CY1108378T1 (el) | 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu | |
| ATE475640T1 (de) | Antagonisten des opioidrezeptors | |
| HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| BRPI0512516A (pt) | composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
| WO2008005368A3 (en) | Piperazines as p2x7 antagonists | |
| WO2004000808A3 (en) | N-substituted piperidine derivatives as serotonin receptor agents | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
| RS51146B (sr) | Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba | |
| WO2004082623A3 (en) | Substituted piperidine compounds | |
| RS53613B1 (en) | COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| DK1814848T3 (da) | 2,3,4-substitueret-cyclopentanoner som terapeutiske midler | |
| ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
| DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |